Skip to main content
//empty //empty
Cboe BZX Real-Time Last Sale USD
Today's Change
Price Quote as of

Today's Trading

Day Low 64.60
Day High 70.90
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.


Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.


A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.


What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.


A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Thinking about trading options or stock in Moderna, Alibaba, Exxon Mobil, Ford, or Coca-Cola?
- PR Newswire - Thu Sep 17, 8:31AM CDT
PR Newswire - PRNW
Thu Sep 17, 8:31AM CDT
NEW YORK , Sept. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, BABA, XOM, F, and KO.
Global UV Infection Control Device Market Could Exceed US$ 640 Million By 2026
- PR Newswire - PRF - Thu Sep 17, 7:50AM CDT
PR Newswire - PRF - CMTX
Thu Sep 17, 7:50AM CDT
, /PRNewswire/ -- In the present global health crisis, UV Light technology can be an important part of the infection control protocols that address infection prevention in the healthcare, hospitality, commercial and residential markets, especially important now more than ever as the world is dealing with the COVID-19 crisis. As UV Light technology continues to improve and costs come down, it is likely that we will see the development of more devices using UV Light for effective cleaning and disinfection. In addition to the human toll, hospitals now have a financial reason to reduce hospital-acquired infections: beginning in 2017, the federal government will dramatically reduce Medicare payments to hospitals that exceed incidences of them and of other conditions. A recent  from industry insider, Industry Research, says that the global UV Infection Control Device market size is projected to reach by 2026, from in 2020, at a CAGR of 6.4% during 2021-2026.  UV Light refers to Ultraviolet light which is outside the visible light spectrum between wavelength ranges of 100 nanometers (nm) to 400 nm. UV Light is classified into three wavelength ranges: UV-C from 100 nm - 280 nm, UV-B from 280 nm - 315 nm, UV-A from 315 nm - 400 nm.   Active Companies from around the market include:   (NASDAQ: AUVI),  (NASDAQ: INO), (NASDAQ: HTBX), ., (NASDAQ: VXRT), (NASDAQ: MRNA).
Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day
- BusinessWire - Thu Sep 17, 5:59AM CDT
BusinessWire - CMTX
Thu Sep 17, 5:59AM CDT
--Phase 3 COVE study of COVID vaccine candidate (mRNA-1273) has enrolled 25,296 participants to date; Phase 3 protocol now available online
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 54.21 +25.24% increase
on 09/08/20
Period Open:69.76
Price movement based on the high, low and last over the given period.
71.64 -5.23% decrease
on 08/26/20
-1.87 (-2.68%) decrease
since 08/17/20
3-Month 54.21 +25.24% increase
on 09/08/20
Period Open:63.31
Price movement based on the high, low and last over the given period.
95.21 -28.69% decrease
on 07/17/20
+4.58 (+7.23%) increase
since 06/17/20
52-Week 13.53 +401.77% increase
on 10/15/19
Period Open:17.66
Price movement based on the high, low and last over the given period.
95.21 -28.69% decrease
on 07/17/20
+50.23 (+284.43%) increase
since 09/17/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies